(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2012 (11.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/137071 A3

(51) **International Patent Classification**:
A61K 39/09 (2006.01) *A61K 39/295* (2006.01)
A61K 39/21 (2006.01) *A61P 31/18* (2006.01)

(21) **International Application Number**:
PCT/IB2012/000857

(22) **International Filing Date**:
6 April 2012 (06.04.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
PCT/CN2011/072481 6 April 2011 (06.04.2011) CN
61/534,088 13 September 2011 (13.09.2011) US
PCT/CN2012/070761
30 January 2012 (30.01.2012) CN
61/609,051 9 March 2012 (09.03.2012) US

(71) **Applicants** *(for all designated States except US)*: **BIOVAXIM LIMITED** [GB/GB]; Finsgate 5-7 Cranwood Street, EC1 V9EE London (GB). **UNIVERSITÉ PARIS DESCARTES** [FR/FR]; 12, rue de l'Ecole de Medecine, F-75006 PARIS (FR). **INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)** [FR/FR]; Le Sextant - 44, bd de Dunkerque, CS 90009, F-13000 MARSEILLE (FR).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **ANDRIEU, Jean-Marie** [FR/FR]; 95, boulevard Saint Michel, F-75005 PARIS (FR). **LU, Louis** [FR/CN]; Room 3201, Building 13, Dong Hu Wan, 8 Li Ze Xi Jie, Wang Jing Area, Chaoyang District, BEIJING 100102 PRC (CN).

(74) **Agent**: **FAIVRE PETIT, Frédérique**; Cabinet Regimbeau, 20, rue de Chazelles, 75847 Paris CEDEX 17 (FR).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
29 November 2012

WO 2012/137071 A3

(54) **Title**: PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND/OR TREATING AN HIV DISEASE IN HUMANS

(57) **Abstract**: The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably *Lactobacillus plantarum*. These compositions are useful for preventing and/or treating an HIV disease in humans.